Reported 53,595 shares, up 26,104 (95.0%) from the prior quarter.
Reported value 124.1%; share count 95.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2023-06-30 | 2429262 |
| 2023-09-30 | 0 |
| 2025-03-31 | 3345593 |
| 2025-06-30 | 3977837 |
| 2025-09-30 | 5232953 |
| 2025-12-31 | 6856015 |
| 2026-03-31 | 2942136 |
| 2026-06-30 | 3369847 |
| 2026-09-30 | 7551000 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q3 2026 | Added | 53,595 | +26,104 (95.0%) | 0.78% | $7,551,000 | 2026-11-16 | |
| Q2 2026 | Reduced | 27,491 | -423 (-1.5%) | 0.3% | $3,369,847 | 2026-08-13 | |
| Q1 2026 | Reduced | 27,914 | -50,584 (-64.4%) | 0.34% | $2,942,136 | 2026-05-13 | |
| Q4 2025 | Reduced | 78,498 | -1,569 (-2.0%) | 0.76% | $6,856,015 | 2026-02-12 | |
| Q3 2025 | Added | 80,067 | +8,096 (11.2%) | 0.6% | $5,232,953 | 2025-11-14 | |
| Q2 2025 | Added | 71,971 | +2,790 (4.0%) | 0.6% | $3,977,837 | 2025-08-12 | |
| Q1 2025 | New | 69,181 | +69,181 (0.0%) | 0.58% | $3,345,593 | 2025-05-13 | |
| Q3 2023 | Reduced | 0 | -87,953 (-100.0%) | 0 | $0 | 2023-11-13 | |
| Q2 2023 | New | 87,953 | +87,953 (0.0%) | 0.45% | $2,429,262 | 2023-08-11 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
419 managers reported PROTAGONIST THERAPEUTICS INC for Q3 2026.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| BlackRock Inc | Added | 10,734,300 | +426,463 | 0.02% | $1,512,355,549 | 9 qtrs |
| FARALLON CAPITAL MANAGEMENT LLC | Added | 6,437,906 | +89,000 | 3.91% | $907,036,576 | 36 qtrs |
| RTW INVESTMENTS LP | Unchanged | 5,061,175 | 0 | 7.19% | $713,068,946 | 29 qtrs |
| UBS Group AG | Added | 3,953,236 | +554,015 | 0.07% | $556,971,420 | 41 qtrs |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Added | 3,668,478 | +39,180 | 0.02% | $516,851,865 | 3 qtrs |
| WELLINGTON MANAGEMENT GROUP LLP | Added | 3,543,702 | +126,921 | 0.09% | $499,272,174 | 9 qtrs |
| STATE STREET CORPORATION | Added | 3,479,267 | +157,713 | 0.01% | $490,193,928 | 41 qtrs |
| VANGUARD CAPITAL MANAGEMENT LLC | Added | 2,895,169 | +41,775 | < 0.01% | $407,900,360 | 3 qtrs |
| Invesco Ltd | Added | 2,837,318 | +496,651 | 0.03% | $399,749,732 | 31 qtrs |
| JOHNSON & JOHNSON | Unchanged | 2,449,183 | 0 | 45.3% | $345,065,393 | 21 qtrs |
Filing details and methodology As reported
- Report period
- September 30, 2026
- Filed
- November 16, 2026
- Filing type
- 13F-HR
- Position type
- Common Stock
Voting authority reported
- Sole
- 11,574
- Shared
- 0
- None
- 42,021
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.